CG
LRMR icon

Cutler Group’s Larimar Therapeutics LRMR Stock Holding History

Cutler Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,200
Closed -$4K – 5782
2021
Q3 		$4K Buy
3,200
+1,600
+100% +$19.2K ﹤0.01% 4631
2021
Q2 		$4K Buy
+1,600
New +$18.1K ﹤0.01% 4608
2016
Q2 		– Sell
-267
Closed -$1K – 7000
2016
Q1 		$1K Sell
267
-333
-56% -$26.3K ﹤0.01% 6030
2015
Q4 		$1K Buy
+600
New +$96.4K ﹤0.01% 5982

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cutler Group's LRMR Position: Q1 2024 in Review

Cutler Group sold out of Larimar Therapeutics (LRMR) in Q1 2024, closing a stake of 400 shares — an estimated $3.12K sold.

Cutler Group first reported a position in LRMR in Q4 2015 and held it in 22 quarters. The position peaked at $34K in Q4 2015. 104 funds tracked by Wall St. Rank hold LRMR as of Q1 2024.

  • Cutler Group reported no remaining Larimar Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 400 Larimar Therapeutics shares in Q1 2024, an estimated $3.12K.
  • Cutler Group first reported a position in Larimar Therapeutics in Q4 2015 and held it in 22 quarters.
  • Cutler Group's Larimar Therapeutics position peaked at $34K in Q4 2015.
  • 104 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.